CJC-1295 Australia: Research Guide, Purity & COA

Compiled by the APL Research TeamSourced directly from peer-reviewed pharmacological literature and clinical guidelines.

Key Takeaways

• Expert Insight: CJC-1295 is a synthetic, DPP-IV-resistant GHRH analog studied in growth-hormone and IGF-1 axis research, available with or without the DAC modification that extends its half-life.
• Quality Assurance: Every batch ships with a Certificate of Analysis (HPLC + MS); select batches receive independent third-party purity verification.
• Research Use Only: CJC-1295 is supplied for in-vitro laboratory research — not for human or animal consumption.

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH, or somatoliberin), the hypothalamic peptide that stimulates growth hormone (GH) secretion from the anterior pituitary. It was developed to overcome the main limitation of native GHRH as a research tool — a plasma half-life of only ~7 minutes, due to rapid degradation by dipeptidyl peptidase IV (DPP-IV). CJC-1295 carries amino-acid substitutions that confer DPP-IV resistance, dramatically extending its duration of action.

It appears in the literature in two forms: CJC-1295 without DAC (Modified GRF 1-29), with a short half-life and pulsatile GH-release profile, and CJC-1295 with DAC (Drug Affinity Complex), which binds albumin for a multi-day half-life and sustained GH elevation.

Australian Peptide Labs supplies CJC-1295 in Australia as a research chemical for in-vitro laboratory work. This page is an overview and sourcing guide; for the receptor pharmacology, see the deep-dive article linked below.

Molecular Profile

Research Applications

CJC-1295 is studied principally within growth-hormone-axis research:

• GH / IGF-1 secretion — as a GHRH-receptor agonist, it is used to study stimulation of GH release and downstream hepatic IGF-1 production.
• Pharmacokinetic modification — a model compound for how DPP-IV resistance and albumin-binding (DAC) extend peptide half-life and change release patterns from pulsatile to sustained.
• Complementary-mechanism studies — frequently studied alongside ghrelin-receptor secretagogues such as ipamorelin, which act through a distinct, complementary pathway.

These are preclinical and in-vitro findings only and do not establish any effect in humans. For the full mechanism — the GHRH signalling cascade and DPP-IV-resistance substitutions — see our deep-dive article: CJC-1295: Growth Hormone Releasing Hormone Analog Research. See also The Growth Hormone Axis and CJC-1295 and Ipamorelin: Synergy in GH Research.

Quality & Certificate of Analysis

Every batch of CJC-1295 is analysed in-house by high-performance liquid chromatography (HPLC) and mass spectrometry (MS), and ships with a batch-specific Certificate of Analysis (COA). HPLC quantifies purity (we specify ≥98%, the High-Tier Research Grade standard), while MS confirms the molecular identity of the peptide — important for distinguishing the DAC and non-DAC forms. Select batches also undergo independent, third-party purity verification.

Learn more: Every CJC-1295 batch certificate · How purity is verified · How to read a COA.

Handling, Reconstitution & Storage

CJC-1295 is supplied lyophilised. Store the lyophilised powder at -20°C, reconstitute with bacteriostatic water following standard protocols, and keep the reconstituted solution refrigerated (2-8°C), protected from light, with freeze-thaw cycles minimised.

• Reconstitution best practices
• Peptide storage & stability
• Reconstitution calculator

Sourcing CJC-1295 for Research in Australia

Australian Peptide Labs supplies CJC-1295 as a research chemical for in-vitro laboratory use only. Orders are dispatched same day from within Australia with a Certificate of Analysis included, with cold-chain handling where required. CJC-1295 is not approved for human therapeutic use and is not for human or animal consumption; researchers are responsible for compliance with TGA regulations and institutional protocols. Confirm on the product listing whether you are ordering the DAC or non-DAC form.

View CJC-1295 / Ipamorelin product details & current purity →

Frequently Asked Questions

Is CJC-1295 legal to buy in Australia? CJC-1295 is supplied strictly as a research chemical for in-vitro laboratory use. It is not approved for human therapeutic use in Australia and is not for human or animal consumption. Researchers are responsible for compliance with Therapeutic Goods Administration (TGA) regulations and their institution's protocols.

How is the purity of CJC-1295 verified? Every batch is analysed in-house by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) and ships with a Certificate of Analysis. Select batches also undergo independent, third-party purity verification.

What is the difference between CJC-1295 with and without DAC? Both are 29-amino-acid GHRH analogs. CJC-1295 without DAC (also called Modified GRF 1-29) has a short half-life of around 30 minutes and produces pulsatile GH release in research models. CJC-1295 with DAC (Drug Affinity Complex) binds albumin to extend its half-life to roughly 8 days, producing sustained elevation. Check the product listing for which form you are ordering.

Does Australian Peptide Labs provide dosing guidance? No. As these compounds are supplied for laboratory research only, we do not provide dosing or administration protocols. Our research library covers reconstitution and concentration calculations for in-vitro work.

How should CJC-1295 be stored and reconstituted? CJC-1295 ships as a lyophilised powder and is stable at -20°C before reconstitution. Reconstitute with bacteriostatic water following standard protocols, then store the solution at 2-8°C, protected from light, and minimise freeze-thaw cycles. See our reconstitution and storage guides for full protocols.

References

1. Teichman, S.L. et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." The Journal of Clinical Endocrinology and Metabolism, 2006. — PubMed: 16352683
2. Ionescu, M., Frohman, L.A "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." The Journal of Clinical Endocrinology and Metabolism, 2006. — PubMed: 17018654
3. Alba, M. et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." American Journal of Physiology. Endocrinology and Metabolism, 2006. — PubMed: 16822960

⚠️ Medical & Regulatory Disclaimer:The information provided in this academic article is intended exclusively for educational and laboratory research purposes. It does NOT constitute medical advice. Compounds discussed are strictly for in-vitro research and development only, and are not intended for human consumption, veterinary use, or clinical treatment. Always adhere to Australian Therapeutic Goods Administration (TGA) regulations and your institution's ethical guidelines when handling research chemicals.